Ironwood Pharmaceuticals (NASDAQ:IRWD) PT Lowered to $12.00

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price objective decreased by equities research analysts at Wells Fargo & Company from $14.00 to $12.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 183.02% from the stock’s current price.

IRWD has been the topic of several other reports. Craig Hallum cut their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $12.00 to $4.00 in a research note on Thursday. Finally, StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Ironwood Pharmaceuticals Stock Performance

IRWD traded up $0.19 during trading on Friday, reaching $4.24. The company had a trading volume of 6,882,154 shares, compared to its average volume of 3,483,929. Ironwood Pharmaceuticals has a 12-month low of $3.79 and a 12-month high of $15.70. The company has a market cap of $663.68 million, a price-to-earnings ratio of -0.62 and a beta of 0.52. The firm’s 50-day simple moving average is $6.36 and its 200 day simple moving average is $8.67.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.20). The firm had revenue of $74.90 million for the quarter, compared to analyst estimates of $105.75 million. Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. The firm’s revenue was down 28.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.25 EPS. On average, sell-side analysts expect that Ironwood Pharmaceuticals will post 0.56 EPS for the current year.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Julie Mchugh sold 22,766 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $6.29, for a total transaction of $143,198.14. Following the completion of the sale, the director now owns 139,528 shares of the company’s stock, valued at $877,631.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Catherine Moukheibir sold 44,426 shares of the company’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the completion of the transaction, the director now directly owns 84,207 shares in the company, valued at approximately $535,556.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Julie Mchugh sold 22,766 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $6.29, for a total transaction of $143,198.14. Following the completion of the sale, the director now owns 139,528 shares in the company, valued at $877,631.12. The disclosure for this sale can be found here. Insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Signaturefd LLC increased its position in shares of Ironwood Pharmaceuticals by 61.4% during the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 822 shares during the period. Daiwa Securities Group Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 331.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,900 shares during the period. CWM LLC boosted its position in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 2,345 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Ironwood Pharmaceuticals by 152.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,645 shares during the period. Finally, GAMMA Investing LLC raised its position in Ironwood Pharmaceuticals by 344.1% in the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.